Forest Laboratories, Inc. Announces Additional Settlement Agreement in BYSTOLIC® Patent Litigation

  Forest Laboratories, Inc. Announces Additional Settlement Agreement in
  BYSTOLIC® Patent Litigation

Business Wire

NEW YORK -- July 22, 2013

Forest Laboratories, Inc. (NYSE: FRX) and Forest Laboratories Holdings, Ltd.
(collectively, "Forest") announced today that they have entered into a
settlement agreement with Amerigen Pharmaceuticals, Inc. and Amerigen
Pharmaceuticals, Ltd. (collectively, "Amerigen") in patent infringement
litigation brought by Forest in response to Amerigen's abbreviated new drug
application (ANDA) seeking approval to market generic versions of Forest's
BYSTOLIC® (nebivolol) tablets. This settlement agreement is in addition to the
previously announced BYSTOLIC® patent infringement settlement agreements with
Hetero Labs Ltd., Alkem Laboratories, Ltd., Indchemie Health Specialties Pvt.
Ltd., Torrent Pharmaceuticals Ltd, and Glenmark Pharmaceuticals Ltd.

Specifically, under the terms of the settlement agreement and subject to
review of the settlement terms by the U.S. Federal Trade Commission, Forest
will provide a license to Amerigen that will permit it to launch its generic
versions of BYSTOLIC® as of the date that is the later of (a) three calendar
months prior to the expiration of U.S. Patent No. 6,545,040, including any
extensions and/or pediatric exclusivities or (b) the date Amerigen receives
final FDA approval of its ANDA, or earlier in certain circumstances.

Similar patent infringement litigation brought by Forest against Actavis,
Inc., and related companies and subsidiaries thereof, remains pending in a
multidistrict litigation established in the U.S. District Court for the
Northern District of Illinois.

About Forest Laboratories

Forest Laboratories' (NYSE: FRX) longstanding global partnerships and track
record developing and marketing pharmaceutical products in the United States
have yielded its well-established central nervous system and cardiovascular
franchises and innovations in anti-infective, respiratory, gastrointestinal
and pain management medicine. Forest’s pipeline, the most robust in its
history, includes product candidates in all stages of development across a
wide range of therapeutic areas. The Company is headquartered in New York, NY.
To learn more, visit www.FRX.com.

Except for the historical information contained herein, this release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve a number of risks and
uncertainties, including the difficulty of predicting FDA approvals, the
acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and
any subsequent SEC filings. Forest assumes no obligation to update
forward-looking statements contained in this release to reflect new
information or future events or developments.

Contact:

Forest Laboratories, Inc.
Frank J. Murdolo, 1-212-224-6714
Vice President - Investor Relations
media.relations@frx.com
 
Press spacebar to pause and continue. Press esc to stop.